New stock news | Kidswant Children Products (301078.SZ) plans to conduct an IPO in Hong Kong. The China Securities Regulatory Commission requires an explanation of the estimated amount of funds to be raised after full exercise of the over-allotment option.
On January 30th, the China Securities Regulatory Commission announced the requirement for disclosure of supplementary materials for overseas issuance and listing (January 26, 2026 - January 30, 2026).
On January 30th, the China Securities Regulatory Commission (CSRC) announced the disclosure requirements for supplemental materials for overseas issuance and listing (January 26, 2026 - January 30, 2026). The CSRC requested that Kidswant Children Products disclose the expected amount of funds to be raised after the full exercise of the over-allotment option; the starting time, specific content, and certification status of the value-added telecommunications business conducted by the company and its subsidiaries; the maximum foreign ownership limit, and the specific basis for continuing to comply with the requirements of the foreign investment access policy after the issuance and listing; detailed description of the company's business model and specific information related to AI big models, including application scenarios and specific functions. According to the disclosure by the Hong Kong Stock Exchange on December 11, 2025, Kidswant Children Products (301078.SZ) submitted documents to the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor.
The prospectus shows that Kidswant Children Products is a leading provider of integrated services for the new consumer market in China's parent-child family, mainly engaged in the maternity, infant, and children's business, including selling maternity, infant, and children's products and providing children's development and parenting services. According to data from Frost & Sullivan, in 2024, the company ranked first in China's maternity, infant, and children's products and services market with a GMV of 13.8 billion yuan, with a market share of 0.3%.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


